Everett, WA – October 14, 2009 – SNBL USA, one of the nation’s leading preclinical testing companies, is pleased to announce the addition of two board-certified pathologists to the SNBL USA team in Q3 2009.
Jeffery Engelhardt, DVM, PhD, DACVP, FIATP has recently joined the SNBL USA pathology team and holds the position of Senior Toxicological Pathologist. Dr. Engelhardt brings with him significant experience and knowledge in the pathology field and is well-versed in many areas of pathology and the drug development industry including: Peer review and primary interpretation of gross, microscopic, and clinical pathology data from toxicology studies; Scientific review of general toxicology study reports and other documents submitted to regulatory agencies; Preparation of expert reports, specialized overviews, and integrated summaries of data derived from nonclinical drug safety studies, such as the CTD overview and summaries and IND overview; and Strategies for nonclinical development programs.
Prior to joining SNBL USA, Dr. Engelhardt has held various positions including President of Engelhardt Consulting, Inc., Executive Director, Toxicology at Amgen, Inc. and Pathology Research Advisor and Preclinical Expert at Eli Lilly and Company.
Meliton Novilla, DVM, PhD, DACVP has also recently joined the SNBL USA pathology team and holds the position of Senior Toxicological Pathologist. Dr. Novilla brings SNBL USA solid expertise and experience in the field of pathology. His breadth of expertise includes thirty years experience as a Toxicologic Pathologist, including gross pathologic, histopathologic, and clinical pathology evaluation of laboratory animals and interpretation, integration and reporting of preclinical data to support the discovery and development of investigational drugs and marketing of chemotherapeutics for humans and animals.
Prior to joining SNBL USA, Dr. Novilla held various positions including Senior Pathologist at WIL Research Laboratories and Senior Research Pathologist at Lilly Research Laboratories.
“Between them, Drs. Engelhardt and Novilla have over fifty-five years of toxicologic pathology experience, extensive experience working with a variety of large pharmaceutical companies and assorted recognized contributions to the industry to date,” said James Klaassen, DVM, PhD, DACVP, vice president of operations, SNBL USA. “We are excited to have two esteemed pathologists on staff reviewing pathology reports and elevating the level of pathology services for SNBL USA clients.”
For more information regarding SNBL USA pathology services, or its preclinical services in general, contact SNBL USA today via info@snblusa.com or +1 (425) 322.1950.
About SNBL USA, Ltd.
Headquartered in Everett, WA, SNBL USA, Ltd. is a preclinical CRO that specializes in nonhuman primate (NHP) and small animal research. Study programs range from regulatory toxicology to customized study designs and disease models. Specialized programs include reproductive toxicology, safety pharmacology, immunotoxicology and carcinogenicity. SNBL USA’s Laboratory Services division intelligently applies extensive experience, comprehensive scientific capabilities, and modern technology to bring outstanding support to all client research. SNBL USA SRC complements SNBL USA in providing quality NHP resources. Through a commitment to investment and excellence, SNBL USA strives to offer the biotechnology and pharmaceutical industries unparalleled quality in both science and service. For additional information call 425.407.0121 or visit www.snblusa.com.
Jeffery Engelhardt, DVM, PhD, DACVP, FIATP has recently joined the SNBL USA pathology team and holds the position of Senior Toxicological Pathologist. Dr. Engelhardt brings with him significant experience and knowledge in the pathology field and is well-versed in many areas of pathology and the drug development industry including: Peer review and primary interpretation of gross, microscopic, and clinical pathology data from toxicology studies; Scientific review of general toxicology study reports and other documents submitted to regulatory agencies; Preparation of expert reports, specialized overviews, and integrated summaries of data derived from nonclinical drug safety studies, such as the CTD overview and summaries and IND overview; and Strategies for nonclinical development programs.
Prior to joining SNBL USA, Dr. Engelhardt has held various positions including President of Engelhardt Consulting, Inc., Executive Director, Toxicology at Amgen, Inc. and Pathology Research Advisor and Preclinical Expert at Eli Lilly and Company.
Meliton Novilla, DVM, PhD, DACVP has also recently joined the SNBL USA pathology team and holds the position of Senior Toxicological Pathologist. Dr. Novilla brings SNBL USA solid expertise and experience in the field of pathology. His breadth of expertise includes thirty years experience as a Toxicologic Pathologist, including gross pathologic, histopathologic, and clinical pathology evaluation of laboratory animals and interpretation, integration and reporting of preclinical data to support the discovery and development of investigational drugs and marketing of chemotherapeutics for humans and animals.
Prior to joining SNBL USA, Dr. Novilla held various positions including Senior Pathologist at WIL Research Laboratories and Senior Research Pathologist at Lilly Research Laboratories.
“Between them, Drs. Engelhardt and Novilla have over fifty-five years of toxicologic pathology experience, extensive experience working with a variety of large pharmaceutical companies and assorted recognized contributions to the industry to date,” said James Klaassen, DVM, PhD, DACVP, vice president of operations, SNBL USA. “We are excited to have two esteemed pathologists on staff reviewing pathology reports and elevating the level of pathology services for SNBL USA clients.”
For more information regarding SNBL USA pathology services, or its preclinical services in general, contact SNBL USA today via info@snblusa.com or +1 (425) 322.1950.
About SNBL USA, Ltd.
Headquartered in Everett, WA, SNBL USA, Ltd. is a preclinical CRO that specializes in nonhuman primate (NHP) and small animal research. Study programs range from regulatory toxicology to customized study designs and disease models. Specialized programs include reproductive toxicology, safety pharmacology, immunotoxicology and carcinogenicity. SNBL USA’s Laboratory Services division intelligently applies extensive experience, comprehensive scientific capabilities, and modern technology to bring outstanding support to all client research. SNBL USA SRC complements SNBL USA in providing quality NHP resources. Through a commitment to investment and excellence, SNBL USA strives to offer the biotechnology and pharmaceutical industries unparalleled quality in both science and service. For additional information call 425.407.0121 or visit www.snblusa.com.
